Aptevo Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Aptevo Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-241.4%

Buyback Yield

Total Shareholder Yield	-241.4%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if APVO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APVO's dividend payments have been increasing.

Dividend Yield vs Market

Aptevo Therapeutics Dividend Yield vs Market

How does APVO dividend yield compare to the market?
Segment	Dividend Yield
Company (APVO)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (APVO) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate APVO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APVO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate APVO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as APVO has not reported any payouts.

Aptevo Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Aptevo Therapeutics Expands on the Potential of Mipletamig

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial Initiated

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies